- Home
- MPT vs CORT Comparison
MPT vs CORT Comparison
Compare MPT & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPT | CORT |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | United States | United States |
| Employees | 118 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | MPT | CORT |
|---|---|---|
| Price | $5.25 | $46.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.00 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 4.9M | 1.8M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.82 |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | N/A | $26.08 |
| Revenue Next Year | $4.75 | $26.98 |
| P/E Ratio | ★ N/A | $56.34 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $4.51 | $28.66 |
| 52 Week High | $6.47 | $91.00 |
Technical Indicators
Market Signals| Indicator | MPT | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 66.37 | 72.82 |
| Support Level | $4.53 | $32.95 |
| Resistance Level | $5.78 | $47.06 |
| Average True Range (ATR) | 0.11 | 1.74 |
| MACD | 0.09 | 0.56 |
| Stochastic Oscillator | 97.26 | 99.38 |
Price Performance
Historical ComparisonAbout MPT Medical Properties Trust Inc. common stock
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. The group's geographic areas are the United States, the United Kingdom, and All other countries.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.